RHP 5.54MTRN 4.28PSMT 0ESLOY 0MSFT -8.48META -4.53HLPR.TO 0VDY.TO -0.65
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

24.04
-0.68 (2.75%)
as of Jun 24, 2026, 8:00:00 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges including a patent cliff and the aftermath of over-earning during the COVID-19 pandemic. The company has made efforts to bolster its drug pipeline through acquisitions, such as Seagen, but many experts express concerns about the lack of earnings momentum and blockbusters to drive growth. While the stock offers an attractive dividend yield (around 6-7%), there is a prevailing sentiment around its long-term growth prospects as reliance on cost-cutting and strategic acquisitions seems insufficient. Analysts highlight the need for a new growth catalyst, particularly in oncology, to reassure investors as the dividend yield may be at risk if substantial progress with new drugs is not achieved. Overall, patience is emphasized by many experts, with a hope that the stock will eventually perform better amid potential improvements in government policies and market conditions.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
AstraZeneca, AZN
DON'T BUY

Pfizer Inc(PFE)

Jan 24, 2007
Hard one to play because it's in the drug space and there is a lot of litigation happening. From a trading perspective, this is a dangerous one to play.
Photo of John ManleyJohn Manley
No
Unlock Rating
$26.82

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Jan 22, 2007
Big pharmaceutical pipelines product lines are getting squeezed and they have to cut costs. Relatively cheap, but the growth rate is not as good as it was.
Photo of John ZechnerJohn ZechnerUnlock Rating
$26.95

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 15, 2007
Like many of the pharmaceuticals, it is a company in transition. Won't go up aggressively, but it pays a decent yield. Historically, these companies have done well and they throw off a lot of free cash flow. New management is expected to cut costs and the company is buying back stock. Good balance sheet. Cheap.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$26.64

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jan 09, 2007
They have a great balance sheet and a yield over 4%. If you own, he would stick with it at this time.
Photo of Charles LannonCharles Lannon
No
Unlock Rating
$26.17

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 04, 2007
Had a number of one time issues that have been happening which has made it a bad investment for the last 5 years. Probably near its bottom now. Would consider it in the $21 area.
Photo of Alex RuusAlex Ruus
No
Unlock Rating
$26.38

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jan 03, 2007
If you want to stay in the pharmaceutical space, he would prefer Eli Lilly (LLY-N).
Photo of Steve MacMillanSteve MacMillan
No
Unlock Rating
$26.29

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 21, 2006
His model price is $39. That’s a 49% positive differential. Looking out 1 year with their earnings, it’s a 15% return, plus the dividend of 4.4% gives a 20% implied rate of return.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.07

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 18, 2006
Pulled a replacement for Lipitor because of poor tests. Wasn’t going to contribute until 2010. Stock dropped. Near its all time low. Pristine balance sheet. Oversold.
Photo of David Taylor, MBA, CFADavid Taylor, MBA, CFA
Owned
Unlock Rating
$25.83

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 12, 2006
Likes the pharmaceutical industry, as it is undervalued. In the long term, it will come back. They will have to cut costs dramatically over the next several years. Cheap. Pays a 4% yield. Defensive. Won’t have dramatic moves.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$25.17

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 05, 2006
One for over 1, 2 and 3 years. Lost their major new blockbuster drug, but it wasn’t due on the market until Lipitor came off patent, 4 years out. Has $38 billion in cash and generates about $14 billion cash a year. Dividend yield of 3.9% and sees it going up a lot.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.82

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 05, 2006
What happened to their drug yesterday will probably mean the stock will stay down for awhile.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$24.82

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Dec 04, 2006
(A Top Pick Aug 3/06. Down 4.2%.) Have sold their consumer products division and have a tremendous amount of cash coming in, giving them a very strong balance sheet. A Hold.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$24.90

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 30, 2006
Pharmaceutical and health care area has been very difficult. Has done better in the last 6 months. A cheap stock.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$27.49

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Nov 22, 2006
Pharmaceutical sector is trading at very low valuations. Prefers Wyeth (WYE-N), which has a better growth profile, better portfolio of drugs. Also don’t have the problem of patent expirations that Pfizer does.
Photo of Alex RuusAlex Ruus
No
Unlock Rating
$27.10

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 07, 2006
His top choice in large pharmas is Eli Lilly (LLY-N). One of the major concerns that pharmacy companies have is patent expiration and generics coming in. This company is not well positioned to fend off generics.
Photo of Ian NakamotoIan NakamotoUnlock Rating
$27.29

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
Showing 586 to 600 of 883 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

MSFT -8.48$365.46
PPL.TO -0.83$66.15
CVE.TO -1.49$35.09
TOU.TO -0.68$59.86
GOOG -1.04$345.04

Today's Top Picks

RHP 5.54$129.77
MTRN 4.28$269.62
PSMT 0$
ESLOY 0$95.66
MSFT -8.48$365.46

Popular Articles

Latest Sell Signals

ATD.TO 1.89$93.76
ITB 5.99$103.32
GLD -11.4$365.92
MU -3.26$1048.51
MU -3.26$1048.51

Most Recent Experts

Brendan Caldwell

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Paul Harris, CFA

Paul Harris, CFA

Harris Douglas Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video